Spectrum Pharmaceuticals, Inc. (SPPI) Tops Q1 EPS by 13c
Tweet
Share
E-mailGet Alerts SPPI Hot Sheet
Price: $1.03 --0%
Financial Fact:
Income (loss) before provision for income taxes: -17.92M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Income (loss) before provision for income taxes: -17.92M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) reported Q1 EPS of $0.40, $0.13 better than the analyst estimate of $0.27. Revenue for the quarter came in at $60 million versus the consensus estimate of $56.93 million.
"The first quarter represents an unprecedented milestone in the history of the company, with approximately $46.5 million reported in net profits and a record EPS of $0.71," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "Our earnings were driven by strong pull through of FUSILEV and a judicious management of our operating expenses. I am proud that, while we are preparing to integrate two key acquisitions, we continue to be focused on growing our core business profitably. Fiscal discipline will remain a core part of our strategy, which we believe will continue to serve our shareholders well in the future."
For earnings history and earnings-related data on Spectrum Pharmaceuticals, Inc. (SPPI) click here.
"The first quarter represents an unprecedented milestone in the history of the company, with approximately $46.5 million reported in net profits and a record EPS of $0.71," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "Our earnings were driven by strong pull through of FUSILEV and a judicious management of our operating expenses. I am proud that, while we are preparing to integrate two key acquisitions, we continue to be focused on growing our core business profitably. Fiscal discipline will remain a core part of our strategy, which we believe will continue to serve our shareholders well in the future."
For earnings history and earnings-related data on Spectrum Pharmaceuticals, Inc. (SPPI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
